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Edited by Laszlo NagyAbstract Treatment of HepG2 with all-trans retinoic acid (RA)
induces expression of fatty acid synthase (FAS) mRNA and pro-
tein. Transfections show that the FAS promoter positively re-
sponds to retinoid X receptor (RXR) but not to RA receptor
(RAR) agonists. Since RXR alone is capable of mediating the
RA response of FAS, the existence of a classical RA-responsive
element in the FAS promoter may be ruled out. Binding sites for
NF-Y and SREBP-1 proved to be essential for the RA response.
Exposure to all-trans RA increased mRNA and protein levels of
SREBP-1, a transcriptional activator for FAS. Overexpression
of a dominant-negative form of SREBP-1c diminished the RA-
dependent increase in promoter activity. These data demonstrate
that RXR ligands can stimulate the expression of a lipogenic
gene solely by inducing transcription and cleavage of mem-
brane-bound SREBP-1c.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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regulatory element-binding protein1. Introduction
The mRNA level and transcription of fatty acid synthase
(FAS), a major lipogenic enzyme, change in response to nutri-
tional signals [1]. Response elements for insulin [2], cAMP [3]
and sterols [4] were identiﬁed in the FAS promoter. A SREBP/
USF-binding element at 65 is crucial for the response of the
FAS promoter to diet [4,5]. An upstream NF-Y-binding
CAAT-box is a prerequisite for this type of dietary response
[4,6].
Retinoids exert their biological eﬀects on development or
diﬀerentiation [7] via the all-trans RA-binding RA receptor
(RAR) and the 9-cis RA-binding retinoid X receptor (RXR),Abbreviations: FAS, fatty acid synthase; FCS, foetal calf serum;
GAPDH, glyceraldehyde-3-phosphate; LXR, liver X receptor; NF-Y,
nuclear factor-Y; RA, retinoic acid; atRA, all-trans retinoic acid;
9cRA, 9-cis RA; RAR, RA receptor; RXR, retinoid X receptor;
SREBP, sterol regulatory element-binding protein; TTNPB, 4-[(E)-2-
(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]ben-
zoic acid; USF, upstream stimulatory factor
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doi:10.1016/j.febslet.2007.05.022which inﬂuence gene expression by binding with or without
their respective ligands to RA-responsive elements. RXRs
are capable of activating transcription either as homodimers
or as the heterodimeric partner of other nuclear receptors [8].
Two groups [9,10] reported a RXR ligand-dependent increase
in triglyceride/fatty acid synthesis due to enhanced expression
of the LXR/RXR target gene, SREBP-1c, a well-established
activator of lipogenesis.
The goal of this study was to see how retinoids per se aﬀect
FAS expression in the human cell line, HepG2. For this pur-
pose, we determined the FAS mRNA/protein levels and de-
ﬁned cis-elements responsible for the response of FAS to RA.2. Materials and methods
2.1. Plasmids
FAS/luciferase plasmids were constructed as described [6].
Mini(156/43) contains the 156/43 region upstream of the FAS
minimal promoter(49/+11)/luciferase fusion. Mutations/deletions
were introduced in selected regions as described [6]. The expression
plasmids containing the entire coding sequences of hRXRa, hRARb
and hLXRa were cloned into pSVSport1 (Invitrogen) and are referred
to as RXRa, RARb and LXRa, respectively. For monitoring transfec-
tion eﬃciency the b-galactosidase reporter plasmid pRSVlacZI was
used.
2.2. Northern blot analysis
RNA from HepG2 cells grown for 24 h in serum-free medium con-
taining all-trans RA or vehicle was extracted, electrophoresed and
transferred onto nylon membranes. The AlkPhos labelling and detec-
tion system (GE Healthcare) was used to detect mRNA signals.
Respective RNA and protein signals were quantitated by densito-
metry.2.3. Real time RT-PCR
cDNA was synthesized using M-MLV RT (Promega). Samples con-
tained 2 ll Master SYBR Green I reaction mix (Roche Applied Sci-
ence), 0.5 lM primers and 40 ng cDNA. qRT-PCR measurements
were performed on a LightCycler (Roche Applied Science). PCR cy-
cles were as follows: 10 min, 95 C and 40 cycles (15 s, 95 C; 5 s, 58–
63 C; 20 s, 72 C). The melting-curve analysis showed the speciﬁcity of
the ampliﬁcations. The threshold cycle, which inversely correlates with
the target mRNA level, was measured as the cycle number at which the
reporter ﬂuorescent emission appears above the background threshold.
The relative mRNA levels were estimated by the standard method
using glyceraldehyde-3-phosphate (GAPDH) as reference. Primer
sequences will be made available upon request.2.4. Western blot analysis
HepG2 cells were incubated for 24 h in serum-free medium prior to
the addition of various ligands (1 lM) for a further 24 h. To suppress
SREBP proteolysis, cholesterol (10 lg/ml) and 25-hydroxycholesterol
(1 lg/ml) were added. Nuclear cell extracts were prepared as describedblished by Elsevier B.V. All rights reserved.
2716 K. Roder et al. / FEBS Letters 581 (2007) 2715–2720[10]. Samples were separated by SDS–PAGE and blotted onto a PVDF
membrane. Antibodies against SREBP-1 from mouse (BD Biosci-
ences), FAS from rabbit and GAPDH from mouse (Abcam), peroxi-
dase-labelled anti-mouse or anti-rabbit IgG and ECL + Plus (GE
Healthcare) were used for detection.
2.5. Transfections
HepG2 cells were transfected as described [6]. Each 6-well transfec-
tion aliquot received 2 lg reporter plasmid, 0.5 lg pRSVlacZI, 0.5 lg
RAR, RXR or LXR expression plasmid. To rule out transfection ef-
fects, empty expression plasmid was used for controls. Glycerol-
shocked cells were incubated in serum-free medium containing ligand
for 36 h.3. Results
3.1. Eﬀect of all-trans RA on FAS mRNA/protein levels
Since hypervitaminosis A increased triglyceride synthesis in
liver [11] and HepG2 cells are able to metabolise vitamin A
to retinoic acid [12], we examined the FAS mRNA level in
RA-treated HepG2 cells. To exclude side eﬀects caused by0
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Fig. 1. RA-dependent increase in FAS mRNA, protein and promoter activity
cells were treated with various concentrations of RA. A representative Northe
changes in FAS mRNA levels after RA treatment normalized to GAPDH
immunoblot is depicted. Values (n = 5) refer to the relative -fold changes in
activation by RXR ligands. The construct 2206/+67 was transfected into
25 lMmethoprene acid, 1 lMTTNPB or vehicle. The -fold promoter stimula
after normalizing to b-galactosidase values. Data shown are the means ± S.D
was cotransfected with pSVSport1 (Invitrogen) or the expression plasmids f
stimulation represents the -fold increase in luciferase activity versus the veh
transfected samples are indicated as *P < 0.01.growth factors/hormones found in FCS, serum-free medium
was used. After 24 h incubation with all-trans RA, the FAS
mRNA amount was increased up to 3.5-fold in a dose-depen-
dent manner (Fig. 1A). Similarly, FAS protein levels were ele-
vated 3-fold (Fig. 1B). GAPDH mRNA/protein levels did not
change after RA treatment and served as controls.
3.2. Eﬀect of retinoids on the FAS promoter
To ﬁnd out whether FAS was transcriptionally regulated by
retinoids, the luciferase construct 2206/+67 was transfected
into HepG2 with or without RARb or RXRa (Fig. 1C and
D). When transfected cells were treated with all-transRA, lucif-
erase activity increased 2-fold (Fig. 1C). All-trans RA concen-
trations up to 0.5 lM were not eﬀective (data not shown).
Due to isomerization of the RAR ligand, all-trans RA, to the
RXR ligand, 9-cis RA [13], RXR activates transcription after
the addition of 9-cis RA or high levels of all-trans RA, whereas
RAR responds to low, more physiological levels of all-trans
RA. Two RXR agonists, 9-cis RA and methoprene acid, in-
creased promoter activity 2.7- and 1.5-fold. The RAR agonist,0
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. (A) Regulation of FAS mRNA levels by all-trans RA (atRA). HepG2
rn blot is shown. Values (means ± S.D.; n = 3) refer to the relative -fold
signals. (B) Regulation of FAS protein levels by all-trans RA. An
normalized FAS protein levels after RA treatment. (C) FAS promoter
HepG2 cells treated with 1 lM all-trans RA, 1 lM 9-cis RA (9cRA),
tion represents the -fold increase in luciferase activity versus the control
. (n = 4). (D) Promoter activation by RXR and its ligands. 2206/+67
or RXRa and/or RARb into ligand-treated cells. The -fold promoter
icle-treated control (n = 4). Statistically signiﬁcant diﬀerences between
K. Roder et al. / FEBS Letters 581 (2007) 2715–2720 27174-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-
1-propenyl]benzoic acid (TTNPB), had no impact on luciferase
activity of HepG2 cells with or without overexpressed RXRa
and RARb, conﬁrming previous results by Tall and colleagues
[14] who showed that the livers of TTNPB-fed mice did not
show any changes in FAS mRNA expression. Untreated,
RXRa-expressing cells showed a slight induction of promoter
activity, whereas cells cotransfected with RARb, but not RA-
treated, had an approximately 50% decreased FAS promoter
activity (Fig. 1D). Currently, we do not know the reason for
this observation. Extracts from HepG2 cells cotransfected with
RXRa and incubated with all-trans RA or 9-cis RA showed a
7- to 8-fold increase in promoter activity. Since neither RARb,
TTNPB, nor physiological concentrations of all-transRA stim-
ulated the FAS promoter, we concluded that all-trans RA does
not induce the promoter via a RAR/RXR-binding RA-respon-
sive element.0
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Fig. 2. FAS promoter deletion analysis to deﬁne RA-responsive regions. (A)
indicated promoter constructs were incubated in the presence or absence o
binding sites in the FAS promoter. (C) Deletion analysis of the 156/43
mutants of the 156/43 promoter in the Mini(156/43) background (n =3.3. Identiﬁcation of a RA-responsive region
To deﬁne the RA-responsive region, 5 0-deletion/luciferase
constructs were cotransfected with a RXRa-expressing plas-
mid. Deletions from 2206 to 157 gave an approximately
average 7-fold induction by all-trans RA (Fig. 2A). A sharp
drop in stimulation was observed between 157 and 50
implying a fundamental role of this region.
The 156/43 section contains three major cis-elements
(Fig. 2B): a SREBP/USF-binding element at 65 [2,4], a
CAAT-box at 100 [3,6] and a SRE at 150 [4]. To determine
if these elements confer the RA signal to the FAS gene, dele-
tions between 156 and 43 were created (Fig. 2C). RA treat-
ment led to a clear stimulation of luciferase activity in cells
with constructs harbouring the deletions, DSRE(151/141),
D(140/131), D(130/122) and D(118/108). In contrast,
luciferase activity in HepG2 cells transfected with FAS/lucifer-
ase vectors containing a deleted CAAT-box (99/83) or+6
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region. The eﬀect of RA was analyzed by transfection using deletion
5).
2718 K. Roder et al. / FEBS Letters 581 (2007) 2715–2720SRE/E-box (71/52) was barely aﬀected by RA. Although
the aforementioned constructs 50/+67, DCAAT-box (99/
83) and DSRE/E-box (71/52) no longer responded to
RA treatment, they still had signiﬁcant basal promoter activity
(4- to 8-fold above the vector-only control), making it unlikely
that a severely compromised transcription initiation is the
cause of the reduced RA response.
The SRE/E-box (68/52) and CAAT-box (99/94) were
mutated in the context of the 1019/+67 and 816/+67 con-
structs, respectively. Whereas 9-cis RA stimulated the
promoter of the transfected wild-type plasmid approximately
5-fold, a construct with the SRE/E-box mutation no longer
responded to the stimulus (Fig. 3A). Furthermore, the SRE/
E-box mutation had only a minor eﬀect on the promoter acti-
vation by the LXR agonist, TO-901317. This is in accordance
with a study [15] reporting that a mutated SRE/E-box margin-
ally inﬂuenced the upregulation of the FAS promoter by an
LXR ligand. Additionally, our data demonstrate that RXR
and LXR additively activate the promoter. The mutated
CAAT-box abolished the RA response of the promoter but
had no eﬀect on its responsiveness to LXR (Fig. 3B). Although
using two diﬀerent plasmid backgrounds for the mutations,
these data clearly underline the importance of the two regula-
tory elements, SRE/E-box and CAAT-box, in their synergistic
activation of the RA-induced promoter, a scenario not unex-0
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Fig. 3. SRE/E-box and CAAT-box mediate the RA response. (A) Point m
transfected with the construct, 1019/+67 or 1019/+67-mutSRE/E-box, and
1 lM 9-cis RA and/or 1 lM TO-901317. For each panel, the -fold promoter
vehicle-treated control after normalization (n = 4). (B) Point mutation of thepected in light of our [6] and others’ work [4] on the regulation
of FAS by SREBP-1 and NF-Y.
3.4. The role of SREBP-1 in the RA regulation of the FAS
promoter
SREBP-1a, SREBP-1c and SREBP-2 are inserted into the
ER membrane as precursors and following cleavage their N-
termini enter into the nucleus where they act as transcription
factors [16]. Interestingly, RXR agonists induced SREBP-1
expression in mouse [9] and HepG2 cells [10]. However, the lat-
ter study was performed with 10% FCS, which may interfere
with the RA treatment. To see whether all-trans RA would af-
fect expression of SREBP-1 and/or SREBP-2 under our exper-
imental conditions, we quantiﬁed SREBP mRNA levels by
qPCR (Fig. 4A). In agreement with the aforementioned stud-
ies, RA stimulation caused an 8-fold increase in SREBP-1c
mRNA. Furthermore, SREBP-1a and SREBP-2 mRNA levels
are increased 2-fold. Immunoblots with antiserum recognizing
SREBP-1a and SREBP-1c revealed a 3- to 5-fold increase in
both the membrane-bound and nuclear SREBP-1 (Fig. 4B) fol-
lowing RA treatment and reﬂect the increase of SREBP-1c
mRNA. For control purposes, cells were incubated with TO-
901317, which led to a several-fold increase in both SREBP-
1 forms. Addition of sterols to the medium could not prevent
the 9-cis RA-dependent increase in processed SREBP-1. These0
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Fig. 4. Involvement of SREBP-1c in the RA-dependent upregulation of FAS promoter activity. (A) Regulation of SREBP mRNA levels by all-trans
RA (atRA). Respective mRNA levels were quantiﬁed by qPCR. Values (n = 3) refer to the relative -fold changes in SREBP and GAPDH mRNA
levels after 2 lM all-transRA treatment. (B) Immunoblot analysis of SREBP-1 protein levels after treatment with RXR and LXR ligands. Left panel:
immunoblot. HepG2 cells were treated with vehicle, 1 lM 9-cis RA (9cRA), all-trans RA (atRA), TO-901317 (TO), or 9-cis RA/TO-901317 (9cRA/
TO). Under sterol-suppressed conditions (*), cells were treated with vehicle or 1 lM 9-cis RA. SREBP-1 antiserum detected precursor and mature
forms of SREBP-1a and SREBP-1c. The various bands of mature SREBP-1 are probably due to post-translational modiﬁcations [8]. Right panel:
quantitated SREBP-1 forms were normalized to GAPDH signals (n = 4). (C) RA-dependent increase in promoter activity is attenuated by
coexpression of a dominant-negative (DN) form of SREBP-1c. Increasing amounts of DN-SREBP-1c were cotransfected with the reporter plasmid
156/+67 into RA-treated HepG2 (n = 3). Statistically signiﬁcant diﬀerences between transfected samples are indicated as *P < 0.05, **P < 0.01.
K. Roder et al. / FEBS Letters 581 (2007) 2715–2720 2719ﬁndings imply a RXR-dependent, direct eﬀect of retinoids on
SREBP-1 processing in HepG2 cells and are in accordance
with a previous study demonstrating SREBP-1, but not
SREBP-2, processing in liver and intestine of mice fed diets
containing the synthetic RXR ligand, LG268 [9]. Increased lev-
els of nuclear SREBP-1 could, in turn, account for the upreg-
ulation of FAS expression.
To clarify the involvement of SREBP-1c in the RA response,
a dominant-negative (DN) form of SREBP-1c was used: a
point mutation was introduced into the N-terminal fragment
of SREBP-1c (amino acids 1–403), replacing tyrosine at amino
acid 320 by alanine. The resulting protein no longer binds to
SRE/E-boxes but is still able to dimerize resulting in decreased
availability of endogenous SREBP-1c [17]. Cotransfection with
the construct 157/+67 and the DN-SREBP-1c mutant dimin-
ished RA stimulation of the promoter up to 30% in a dose-
dependent manner (Fig. 4C) corroborating SREBP-1c as a
mediator of the RA-induced stimulation of FAS expression.4. Discussion
The RA response appears to be mediated by two elements in
the proximal FAS promoter: the NF-Y-binding CAAT-box(100) and the SREBP/USF-binding SRE/E-box (65). The
NF-Y-binding site is required for the sterol regulation of the
FAS promoter in cell lines and carbohydrate activation in pri-
mary hepatocytes [4]. Whereas in the ﬁrst scenario the NF-Y-
binding site but not its neighbouring Sp1-binding site (85) is
important, full response to carbohydrates has an absolute
requirement for both sequences to be intact. Since SREBP-
1a levels are higher than SREBP-1c levels in cell lines and
SREBP-1c is the major isoform in liver [16], the authors
proved that SREBP-1c uses NF-Y and Sp1 as indispensable
co-regulators, while SREBP-1a requires mainly NF-Y. Inter-
estingly, we observed that the Sp1-binding motif (85) does
play a role in the RA response since its mutation diminished
upregulation of FAS promoter activity by almost 50% (data
not shown), thus pointing towards an involvement of the
SREBP-1c isoform in the RA response. Our ﬁndings are in
agreement with studies that show that RXR agonists enhance
SREBP-1c expression [9,10]. Two LXR/RXR-binding sites in
the SREBP-1c promoter mediate not only the response of
SREBP-1c to retinoids but also to LXR ligands, coordinating
cholesterol homeostasis with lipogenesis. A recent report [18]
described a central role for LXR in insulin-mediated activation
of SREBP-1c transcription and stimulation of fatty acid syn-
thesis in liver. Interestingly, the activation of LXR by
2720 K. Roder et al. / FEBS Letters 581 (2007) 2715–2720TO-901317 leads to the induction of SREBP-1c expression and
precursor protein, but not of its mature nuclear form [19]. The
LXR-induced SREBP-1c precursor, however, is rapidly
cleaved on acute exposure to insulin via a phosphatidylinositol
3-kinase-dependent mechanism. It remains to be shown
whether insulin is also necessary for processing immature
SREBP-1c induced by retinoids in vivo. Since we used serum-
free medium, we can rule out the involvement of insulin during
processing of SREBP-1c in RA-treated HepG2 cells. Our data
suggest a direct eﬀect of RA treatment on the proteolysis of
SREBP-1. Indeed, preliminary data show a decrease of Insig-
2 mRNA after RA treatment [Lei Zhang, unpublished data].
We also present evidence that not only SREBP-1c but also
SREBP-1a or SREBP-2, whose mRNA levels are increased
approximately 2-fold after RA treatment, could convey the
RA signal to the FAS promoter. Similarly, increased
SREBP-1a/SREBP-1c mRNA levels were noticed after stimu-
lating CaCo-2 cells with an LXR ligand [20].
Due to the aforementioned studies it is reasonable to assume
that retinoids aﬀect FAS expression via formation of LXR/
RXR heterodimers binding to their recognition sequences in
the SREBP-1c promoter. However, recent data support the
existence of a well-conserved LXR/RXR-binding site in the
FAS promoter [15] since synthetic LXR ligands induced
FAS expression without changes in the SREBP-1c mRNA lev-
els. The authors concluded that the coregulation of FAS by
both SREBP and LXR might serve to balance its expression
under ﬂuctuating sterol conditions. Indeed, we noticed a minor
contribution of the LXR/RXR-binding site at 650 to the RA
response (data not shown).
In summary, our results support an essential contribution of
the SREBP-binding motif to the stimulatory eﬀect of retinoids
on the FAS promoter and together with other studies [9,10]
help to explain the cause of elevated triglyceride levels after
administering retinoids to animals at the molecular level.
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